Cerus (CERS) Earnings Date & Reports

Key Takeaways

• Cerus reported third quarter 2026 product revenue of $57.7 million, up 10% year over year, with total revenue of $64.0 million including government contracts.
• The company posted breakeven earnings per share of $0.00, beating the consensus estimate for a $0.01 loss.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $5.7 million, marking a tenth consecutive positive quarter.
• Management reaffirmed full-year 2026 product revenue guidance of $229 million to $231 million, including IFC sales of $23 million to $25 million.
• Cerus announced positive top-line results from its Phase 3 RedeS study of the INTERCEPT red blood cell system, while the European CE mark timeline for red cells moved to late 2027.
• For more detail, explore the ticker's Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover automated market insights by exploring Trending AI Robots.

Earnings Context and Why It Matters

Cerus Corporation is focused on safeguarding the global blood supply through its INTERCEPT Blood System, which reduces pathogens in platelets, plasma, and other blood components. The third quarter results matter because they test whether the company can sustain double-digit product growth while simultaneously improving its profitability profile. In recent quarters, management has steadily narrowed GAAP (Generally Accepted Accounting Principles) losses and delivered consistent positive adjusted EBITDA, signaling progress toward breakeven. Investors are also watching the shift toward higher-margin IFC (INTERCEPT Fibrinogen Complex) kit sales and the timing of key regulatory milestones, including red blood cell and INT200 device approvals. This report provides an important checkpoint on both the commercial momentum and the path toward sustainable profitability.

Reported Results

Cerus reported third quarter 2026 product revenue of $57.7 million, a 10% increase over the prior-year period, driven by growing demand for IFC and INTERCEPT platelets in the United States and by EMEA (Europe, Middle East, and Africa) placements of its next-generation INT200 illuminator. Total revenue, including government contract revenue of $6.3 million, was $64.0 million. North American product revenue rose 12%, while EMEA product revenue increased 5%, partly offset by foreign exchange headwinds of roughly 2%.

On the bottom line, the company reported breakeven earnings per share of $0.00, ahead of the consensus estimate for a $0.01 loss. On a GAAP basis, Cerus recorded a net loss of approximately $0.55 million. Product gross margin was 52.4%, compared with 53.4% a year earlier but up from 51.4% in the second quarter, supported by the continued conversion of IFC sales to a kit-based model. IFC revenue reached $5.6 million, up from $3.9 million a year ago, with roughly 90% of IFC sales shipped in kit form.

Adjusted EBITDA improved to $5.7 million, the tenth consecutive positive quarter, and operating cash flow swung to a positive $3.0 million. Management reaffirmed full-year 2026 product revenue guidance of $229 million to $231 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, saving time while surfacing higher-conviction setups. For investors tracking names like Cerus Corporation (CERS), the AI Screener offers a streamlined way to monitor signals and compare opportunities across the broader healthcare and medical technology landscape.

Market Reaction and Investor Sentiment

Sentiment heading into the report had already cooled following a period of decelerating product growth, and the market's initial reaction reflected a more cautious tone. Despite the earnings beat and the positive RedeS readout, shares slipped in after-hours trading as investors weighed slower top-line momentum and the extended timelines for two important regulatory catalysts. The headline results appeared clean — breakeven earnings versus an expected loss, a reaffirmed guidance range, and a genuine pipeline milestone — but the details highlighted a continued slowdown in growth from 24% in the first quarter to roughly 10% in the third. Slower EMEA expansion tied to geopolitical disruptions and deferred orders, along with the shift of the European CE mark for red cells to late 2027, gave investors reasons to temper enthusiasm even as profitability and cash generation improved.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should monitor whether Cerus can convert its improving profitability into sustained bottom-line momentum. The company reaffirmed its full-year product revenue outlook, implying fourth-quarter product revenue of roughly $60 million to $62 million, which points to more modest growth as the year closes. Watching whether North American platelet and IFC volumes continue to outpace the underlying market will be central to the story.

Regulatory timelines remain a key swing factor. Management now expects the European CE mark for the INTERCEPT red blood cell system in late 2027, later than the first-half 2027 timing previously cited. Separately, the FDA (U.S. Food and Drug Administration) has requested additional data on the INT200 platelet device PMA (Premarket Approval) application, meaning approval in the first half of 2027 is no longer assured. These milestones matter because they represent meaningful longer-term revenue opportunities.

On the financial side, the balance sheet warrants attention. Cerus reported cash and investments of about $57.1 million against term debt and revolver borrowings, and the company is refreshing its shelf registration, which preserves flexibility but also introduces potential dilution optionality. Gross margin trends, the ongoing IFC kit conversion, and the company's path toward GAAP profitability will be closely watched in subsequent quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations